Assisted intelligence for intensive care

At AlgoDx, the premise underlying all our research is the final product’s reliability. Our research methods are based on gold standards used in medical device and pharmaceutical development. We use a scientific, evidence-based approach with regulatory requirements in mind.

NAVOY® product suite

The NAVOY® portfolio includes machine learning algorithms intended to assist clinical decision support in intensive care. Developed for conditions with high unmet medical need, these algorithms are designed to generate robust clinical evidence for product claims, covering clinical and health-economic benefits as well as potential risks.

AlgoDx intensive care proprietary pipeline as of July 2022

                              
Pre-clinical
R&D
 
Regulatory clearance
EU & US
 
Clinical validation
in intensive care
 
Post-marketing clinical follow-up
 
NAVOY® Sepsis
                                                    
NAVOY® Acute Kidney Injury
 
                                                                           
Undisclosed Therapeutic Indication                                      
Ongoing
Complete

           

Clinical trials – AlgoDx sponsored clinical research

For more information on our ongoing clinical projects in intensive care, visit clinicaltrials.gov

ExPRESS

Early Prediction of Sepsis in Hospitalized Patients Using a Machine Learning Algorithm, a Randomized Clinical Validation Trial.

Protocol number: NCT04570618

GENIUS

Integration and Evaluation of a Machine Learning Algorithm for Sepsis Prediction in an Electronic Health Record System a Prospective Observational Study.

Protocol number: NCT05095220

AKI-SE-02

Clinical validation of NAVOY® Acute Kidney Injury in ICU patients.

Protocol number: NCT05424874

 

AlgoDx products in the clinical workflow – case study: NAVOY® Sepsis